title: Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Yanada
authors.forename: Xuelin
authors.initials: X
authors.lastname: Huang
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Manero
authors.forename: Susan
authors.initials: S
authors.lastname: O'brien
authors.forename: Farhad
authors.initials: F
authors.lastname: Ravandi
authors.forename: Gautam
authors.initials: G
authors.lastname: Borthakur
authors.forename: Stefan
authors.initials: S
authors.lastname: Faderl
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Issa
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.forename: Elihu
authors.initials: E
authors.lastname: Estey
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D016016:Proportional Hazards Models; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents